RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Clinical trials for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA explained in plain language.
Never miss a new study
Get alerted when new RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA trials appear
Sign up with your email to follow new studies for RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to heal wounds in rare skin disease
Disease control Recruiting nowThis study tests whether adding IV IgG treatment to standard VYJUVEK therapy can help wounds heal faster and reduce blistering in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin condition. Eight participants will receive IV IgG and be monitored …
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: M. Peter Marinkovich • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New eye drops aim to stop painful cornea scratches in rare skin disease
Disease control Recruiting nowThis study tests an eye drop called KB803 for people with dystrophic epidermolysis bullosa (DEB), a rare genetic condition that causes fragile skin and repeated cornea scratches. The trial will include 16 people aged 6 months and older. Each person will receive both KB803 and a p…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE3 • Sponsor: Krystal Biotech, Inc. • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Lab-Grown skin patch could heal wounds for people with butterfly disease
Disease control Recruiting nowThis study tests a new skin graft made from a patient's own cells, genetically modified to produce a missing protein that causes fragile skin in recessive dystrophic epidermolysis bullosa (RDEB). The graft is designed to be permanent and aims to heal wounds safely and effectively…
Matched conditions: RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
Phase: PHASE1, PHASE2 • Sponsor: CHU de Quebec-Universite Laval • Aim: Disease control
Last updated May 07, 2026 18:38 UTC